KRAS G12R Mutations in Pancreatic Cancer: Research Considerations and Next Steps
By Elizabeth Auckley, MD, Stephanie Yohay, MD, Mandana Kamgar, MD - Last Updated: February 14, 2025Drs. Elizabeth Auckley, Stephanie Yohay, and Mandana Kamgar of the Medical College of Wisconsin discuss their research on the efficacy of MEK inhibitor-based therapy for metastatic pancreatic ductal adenocarcinoma in this three-part interview.
Advertisement
In the final part of this discussion, the challenges in designing and conducting clinical trials for this subgroup are explained, and the future of MEK inhibitor research for pancreatic cancer is considered.
Advertisement
Related Posts
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.